Back to top
more

BioCryst Pharmaceuticals (BCRX)

(Delayed Data from NSDQ)

$9.67 USD

9.67
2,329,245

-0.40 (-3.97%)

Updated Aug 20, 2026 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.94%
2Buy18.22%
3Hold10.27%
4Sell5.79%
5Strong Sell3.20%
S&P50011.55%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value A Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 43% (107 out of 247)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Is the Options Market Predicting a Spike in BioCryst (BCRX) Stock?

by Zacks Equity Research

Investors need to pay close attention to BioCryst (BCRX) stock based on the movements in the options market lately.

    Zacks Equity Research

    Implied Volatility Surging for BioCryst (BCRX) Stock Options

    by Zacks Equity Research

    Investors in BioCryst Pharmaceuticals, Inc. (BCRX) need to pay close attention to the stock based on moves in the options market lately.

      Zacks Equity Research

      What's in the Cards for Ecolab (ECL) this Earnings Season?

      by Zacks Equity Research

      Ecolab Inc. (ECL), a leading provider of water, hygiene and energy technologies and services, is expected to report first-quarter 2017 results on May 2.

        Zacks Equity Research

        Can Cardinal Health (CAH) Bring On a Beat in Q3 Earnings?

        by Zacks Equity Research

        Cardinal Health (CAH), a global player in the healthcare services and products space, is set to report third-quarter fiscal 2017 results on May 1, before the bell.

          Zacks Equity Research

          Will Baxter International (BAX) Disappoint in Q1 Earnings?

          by Zacks Equity Research

          Baxter International Inc. (BAX) is scheduled to report first-quarter 2017 earnings on Apr 26, before the opening bell.

            Zacks Equity Research

            Is a Surprise in Store for C.R. Bard (BCR) in Q1 Earnings?

            by Zacks Equity Research

            CR Bard Inc. (BCR) is scheduled to report first-quarter 2017 earnings, after market close on Apr 26.

              Zacks Equity Research

              Will Stryker (SYK) Deliver a Beat this Earnings Season?

              by Zacks Equity Research

              Stryker Corporation (SYK), a leading player in the medical technology space, is set to report first-quarter 2017 results on Apr 25 after the bell.

                Zacks Equity Research

                Teva Launches Authorized Generic of Allergan's Minastrin

                by Zacks Equity Research

                Teva Pharmaceutical Industries Ltd. (TEVA) recently launched an authorized generic version of Allergan plc???s (AGN) oral contraceptive, Minastrin 24 Fe1, in the U.S.

                  Zacks Equity Research

                  Jazz Initiates Phase III Study for Narcolepsy Candidate

                  by Zacks Equity Research

                  Jazz Pharmaceuticals plc (JAZZ) recently announced the initiation of patient enrollment in a phase III study evaluating the efficacy and safety of its pipeline candidate, JZP-258, for the potential treatment of adult narcolepsy patients.

                    Zacks Equity Research

                    Conatus Pharma (CNAT) Incurs Wider-than-Expected Loss in Q4

                    by Zacks Equity Research

                    Conatus Pharmaceuticals Inc. (CNAT) reported fourth-quarter 2016 loss of 35 cents per share, wider than both the Zacks Consensus Estimate of a loss of 32 cents and the year-ago figure of 30 cents.